Dendritic Spine Pathology in Neurodegenerative Diseases

Annual Review of Pathology: Mechanisms of Disease

Volumn 11, Issue , 2016, Pages 221-250

  Herms, Jochen ^a,b   Dorostkar, Mario M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; Dementia; Huntington's disease; Parkinson's disease; Synapse

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DENDRITIC SPINE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRION DISEASE; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; SYNAPSE; TAUOPATHY; ANIMAL; PATHOLOGY;

ANIMALS; DENDRITIC SPINES; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84971280110     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012615-044216     Document Type: Review

References (210)

1. Fu M, Zuo Y. 2011. Experience-dependent structural plasticity in the cortex. Trends Neurosci. 34:177-87
2. Rocher AB, KinsonMS, Luebke JI. 2008. Significant structural but not physiological changes in cortical neurons of 12-month-old Tg2576 mice. Neurobiol. Dis. 32:309-18
3. Yuste R, Bonhoeffer T. 2004. Genesis of dendritic spines: insights from ultrastructural and imaging studies. Nat. Rev. Neurosci. 5:24-34
4. Holtmaat AJGD, Trachtenberg JT, Wilbrecht L, Shepherd GM, Zhang X, et al. 2005. Transient and persistent dendritic spines in the neocortex in vivo. Neuron 45:279-91
5. Grutzendler J, Kasthuri N, Gan WB. 2002. Long-term dendritic spine stability in the adult cortex. Nature 420:812-16
6. Schikorski T, StevensCF. 1999. Quantitative fine-structural analysis of olfactory cortical synapses. PNAS 96:4107-12
7. Yuste R, Bonhoeffer T. 2001. Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annu. Rev. Neurosci. 24:1071-89
8. Lendvai B, Stern EA, Chen B, Svoboda K. 2000. Experience-dependent plasticity of dendritic spines in the developing rat barrel cortex in vivo. Nature 404:876-81
9. Yang G, Pan F,Gan W-B. 2009. Stably maintained dendritic spines are associated with lifelongmemories. Nature 462:920-24
10. Xu T, Yu X, Perlik AJ, TobinWF, Zweig JA, et al. 2009. Rapid formation and selective stabilization of synapses for enduring motor memories. Nature 462:915-19
11. Mostany R, Anstey JE, Crump KL, Maco B, Knott G, Portera-Cailliau C. 2013. Altered synaptic dynamics during normal brain aging. J. Neurosci. 33:4094-104
12. Jung CKE, Herms J. 2014. Structural dynamics of dendritic spines are influenced by an environmental enrichment: an in vivo imaging study. Cereb. Cortex 24:377-84
13. Falkenberg T, Mohammed AK, Henriksson B, Persson H, Winblad B, Lindefors N. 1992. Increased expression of brain-derived neurotrophic factor mRNA in rat hippocampus is associated with improved spatial memory and enriched environment. Neurosci. Lett. 138:153-56
14. Beaulieu J-M, Gainetdinov RR, Caron MG. 2009. Akt/GSK3 signaling in the action of psychotropic drugs. Annu. Rev. Pharmacol. Toxicol. 49:327-47
15. Dewachter I, Ris L, Jaworski T, Seymour CM, Kremer A, et al. 2009. GSK3β, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at serine-9. Neurobiol. Dis. 35:193-200
16. Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, et al. 2007. LTP inhibits LTD in the hippocampus via regulation of GSK3β. Neuron 53:703-17
17. Ochs SM, Dorostkar MM, Aramuni G, Schon C, Filser S, et al. 2014. Loss of neuronal GSK3βreduces dendritic spine stability and attenuates excitatory synaptic transmission via β-catenin. Mol. Psychiatry 20:482-89
18. Shirao T, González-Billault C. 2013. Actin filaments and microtubules in dendritic spines. J. Neurochem. 126:155-64
19. Thomas MG, Pascual ML, Maschi D, Luchelli L, Boccaccio GL. 2014. Synaptic control of local translation: The plot thickens with new characters. Cell. Mol. Life Sci. 71:2219-39
20. Rahimi F, Bitan G. 2012. Non-Fibrillar Amyloidogenic Protein Assemblies-Common Cytotoxins Underlying Degenerative Diseases. Dordrecht, Neth.: Springer
21. Golgi C. 1873. Sulla struttura della sostanza grigia del cervello (comunicazione preventiva). Gazz. Med. Ital. Lomb. 33:244-46
22. Desmond NL, Levy WB. 1985. Granule cell dendritic spine density in the rat hippocampus varies with spine shape and location. Neurosci. Lett. 54:219-24
23. Andrade JP, Madeira MD, Paula-Barbosa MM. 1998. Differential vulnerability of the subiculum and entorhinal cortex of the adult rat to prolonged protein deprivation. Hippocampus 8:33-47
24. Andrade JP, Castanheira-Vale AJ, Paz-Dias PG,Madeira MD, Paula-Barbosa MM. 1996. The dendritic trees of neurons from the hippocampal formation of protein-deprived adult rats. A quantitative Golgi study. Exp. Brain Res. 109:419-33
25. Ramón y Cajal S. 1991. Cajal's Degeneration and Regeneration of the Nervous System. New York: Oxford Univ. Press
26. Holtmaat A, Randall J, CaneM. 2013. Optical imaging of structural and functional synaptic plasticity in vivo. Eur. J. Pharmacol. 719:128-36
27. Maco B, Holtmaat A, Jorstad A, Fua P, Knott GW. 2014. Correlative in vivo 2-photon imaging and focused ion beam scanning electron microscopy: 3D analysis of neuronal ultrastructure. Methods Cell Biol. 124:339-61
28. Blazquez-Llorca L,HummelE,Zimmerman H, ZouC,Burgold S, et al. 2015. Correlation of two-photon in vivo imaging and FIB/SEM microscopy. J. Microsc. 259:129-36
29. Murthy VN, Schikorski T, Stevens CF, Zhu Y. 2001. Inactivity produces increases in neurotransmitter release and synapse size. Neuron 32:673-82
30. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS. 2000. PSD-95 involvement in maturation of excitatory synapses. Science 290:1364-68
31. Biesemann C, Gronborg M, Luquet E, Wichert SP, Bernard V, et al. 2014. Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting. EMBO J. 33:157-70
32. Coleman PD, Riesen AH. 1968. Environmental effects on cortical dendritic fields. I. Rearing in the dark. J. Anat. 102:363-74
33. JonesWH, Thomas DB. 1962. Changes in the dendritic organization of neurons in the cerebral cortex following deafferentation. J. Anat. 96:375-81
34. MatthewsMR, Powell TPS. 1962. Some observations on transneuronal cell degeneration in the olfactory bulb of the rabbit. J. Anat. 96:89-102.3
35. Keck T, Mrsic-Flogel TD, Vaz Afonso M, Eysel UT, Bonhoeffer T, Hubener M. 2008. Massive restructuring of neuronal circuits during functional reorganization of adult visual cortex. Nat. Neurosci. 11:1162-67
36. Halpain S, Hipolito A, Saffer L. 1998. Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin. J. Neurosci. 18:9835-44
37. HasbaniMJ, SchliefML, Fisher DA, GoldbergMP.2001. Dendritic spines lost during glutamate receptor activation reemerge at original sites of synaptic contact. J. Neurosci. 21:2393-403
38. Tolino M, Köhrmann M, Kiebler MA. 2012. RNA-binding proteins involved in RNA localization and their implications in neuronal diseases. Eur. J. Neurosci. 35:1818-36
39. Campbell JN, Register D, Churn SB. 2011. Traumatic brain injury causes an FK506-sensitive loss and an overgrowth of dendritic spines in rat forebrain. J. Neurotrauma 29:201-17
40. Tong L, Prieto GA, Kramár EA, Smith ED, Cribbs DH, et al. 2012. Brain-derived neurotrophic factordependent synaptic plasticity is suppressed by interleukin-1βvia p38 mitogen-activated protein kinase. J. Neurosci. 32:17714-24
41. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, et al. 2009. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 29:3442-52
42. Fiala JC, Spacek J, Harris KM. 2002. Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res. Rev. 39:29-54
43. Peters A, Sethares C, Moss MB. 1998. The effects of aging on layer 1 in area 46 of prefrontal cortex in the rhesus monkey. Cereb. Cortex 8:671-84
44. Brettschneider J, Van Deerlin VM, Robinson JL, Kwong L, Lee EB, et al. 2012. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol. 123:825-39
45. Filser S, Ovsepian SV, Masana M, Blazquez-Llorca L, Brandt Elvang A, et al. 2014. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol. Psychiatry 77:729-39
46. Nhan H, Chiang K, Koo E. 2015. The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes. Acta Neuropathol. 129:1-19
47. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, et al. 2003. APP Processing and synaptic function. Neuron 37:925-37
48. Cirrito JR,YamadaKA, Finn MB, Sloviter RS,BalesKR, et al. 2005. Synaptic activity regulates interstitial fluid amyloid-βlevels in vivo. Neuron 48:913-22
49. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, et al. 2006. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45:12393-99
50. DeMattos RB, Lu J, Tang Y, Racke MM, DeLong CA, et al. 2012. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron 76:908-20
51. Brendel M, Jaworska A, Griessinger E, Rotzer C, Burgold S, et al. 2015. Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models. PLOS ONE 10:e0116678
52. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, et al. 2012. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367:795-804
53. Bittner T, Burgold S, Dorostkar M, Fuhrmann M, Wegenast-Braun B, et al. 2012. Amyloid plaque formation precedes dendritic spine loss. Acta Neuropathol. 124:797-807
54. Dorostkar MM, Burgold S, Filser S, Barghorn S, Schmidt B, et al. 2014. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model. Brain 137:3319-26
55. Burgold S, Filser S, Dorostkar MM, Schmidt B,Herms J. 2014. In vivo imaging reveals sigmoidal growth kinetic of β-amyloid plaques. Acta Neuropathol. Commun. 2:30
56. Burgold S, Bittner T, Dorostkar M, Kieser D, Fuhrmann M, et al. 2010. In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol. 121:327-35
57. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, et al. 2009. Oligomeric amyloid βassociates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. PNAS 106:4012-17
58. Wu H-Y, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, et al. 2010. Amyloid β induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J. Neurosci. 30:2636-49
59. Kirkwood CM, Ciuchta J, Ikonomovic MD, Fish KN, Abrahamson EE, et al. 2013. Dendritic spine density, morphology, and fibrillar actin content surrounding amyloid-β plaques in a mouse model of amyloid-βdeposition. J. Neuropathol. Exp. Neurol. 72:791-800
60. Bittner T, Fuhrmann M, Burgold S,Ochs SM, Hoffmann N, et al. 2010. Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLOS ONE 5:e15477
61. Adalbert R, Nogradi A, Babetto E, Janeckova L, Walker SA, et al. 2009. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain 132:402-16
62. Sǐsková Z, Justus D, Kaneko H, Friedrichs D, Henneberg N, et al. 2014. Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer's disease. Neuron 84:1023-33
63. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold K-H, et al. 2008. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 321:1686-89
64. Chakroborty S, StutzmannG. 2011. Early calcium dysregulation in Alzheimer's disease: setting the stage for synaptic dysfunction. Sci. China Life Sci. 54:752-62
65. Kuchibhotla KV, Goldman ST, Lattarulo CR,Wu H-Y, Hyman BT, Bacskai BJ. 2008. Aβplaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59:214-25
66. Garcia-Marin V, Blazquez-Llorca L, Rodriguez J-R, Boluda S, Muntane G, et al. 2009. Diminished perisomatic GABAergic terminals on cortical neurons adjacent to amyloid plaques. Front. Neuroanat. 3:28
67. Benilova I, Karran E, De Strooper B. 2012. The toxic Aβoligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15:349-57
68. Resenberger UK, Harmeier A, Woerner AC, Goodman JL, Müller V, et al. 2011. The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J. 30:2057-70
69. Benilova I, De Strooper B. 2013. Promiscuous Alzheimer's amyloid: yet another partner. Science 341:1354-55
70. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, et al. 2013. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 73:104-19
71. Koffie RM, Hashimoto T, Tai H-C, Kay KR, Serrano-Pozo A, et al. 2012. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain 135:2155-68
72. Fowler SW, Chiang ACA, Savjani RR, Larson ME, Sherman MA, et al. 2014. Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J. Neurosci. 34:7871-85
73. Larson ME, Lesné SE. 2012. Soluble Aβoligomer production and toxicity. J. Neurochem. 120:125-39
74. Zempel H, Mandelkow EM. 2012. Linking amyloid-βand tau: amyloid-βinduced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener. Dis. 10:64-72
75. Lashuel HA, Lansbury PT Jr. 2006. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q. Rev. Biophys. 39:167-201
76. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, et al. 2012. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15:1227-35
77. Boehm J. 2013. A 'danse macabre': tau and Fyn in STEP with amyloid beta to facilitate induction of synaptic depression and excitotoxicity. Eur. J. Neurosci. 37:1925-30
78. Mori C, Spooner ET,Wisniewski KE, Wisniewski TM, Yamaguchi H, et al. 2002. Intraneuronal Aβ42 accumulation in Down syndrome brain. Amyloid 9:88-102
79. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, et al. 2000. Intraneuronal Aβ42 accumulation in human brain. Am. J. Pathol. 156:15-20
80. Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M, et al. 2010. Intraneuronal amyloid βaccumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol. Dis. 37:731-37
81. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. 2013. Accumulation of intraneuronal β-amyloid 42 peptides is associated with early changes in microtubule-associated protein 2 in neurites and synapses. PLOS ONE 8:e51965
82. Blair JA, Siedlak SL,Wolfram JA, Nunomura A, CastellaniRJ, et al. 2014. Accumulation of intraneuronal amyloid-βis common in normal brain. Curr. Alzheimer Res. 11:317-24
83. Shie F-S, LeBoeur RC, Jin L-W. 2003. Early intraneuronal Aβdeposition in the hippocampus of APP transgenic mice. NeuroReport 14:123-29
84. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, et al. 2002. Intraneuronal Alzheimer Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161:1869-79
85. Umeda T, Tomiyama T, Kitajima E, Idomoto T, Nomura S, et al. 2012. Hypercholesterolemia accelerates intraneuronal accumulation of Aβoligomers resulting in memory impairment in Alzheimer's disease model mice. Life Sci. 91:1169-76
86. Takuma K, Fang F, ZhangW, Yan S, Fukuzaki E, et al. 2009. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-βand neuronal dysfunction. PNAS 106:20021-26
87. Zhao W, Dumanis SB, Tamboli IY, Rodriguez GA, Jo LaDu M, et al. 2014. Human APOE genotype affects intraneuronalAβ1-42 accumulation in a lentiviral gene transfer model. Hum. Mol. Genet. 23:1365-75
88. Mahley RW, Weisgraber KH, Huang Y. 2006. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. PNAS 103:5644-51
89. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. 1996. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J. Neurosci. 16:5795-811
90. Oakley H, Cole SL, Logan S, Maus E, Shao P, et al. 2006. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26:10129-40
91. Moon M, Hong H-S, Nam DW, Baik SH, Song H, et al. 2012. Intracellular amyloid-βaccumulation in calcium-binding protein-deficient neurons leads to amyloid-βplaque formation in animal model of Alzheimer's disease. J. Alzheimer's Dis. 29:615-28
92. Christensen DZ, Huettenrauch M, Mitkovski M, Pradier L, Wirths O. 2014. Axonal degeneration in an Alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal Aβaccumulation. Front. Aging Neurosci. 6:139
93. Eimer W, Vassar R. 2013. Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation. Mol. Neurodegener. 8:2
94. Villar AJ, Belichenko PV, Gillespie AM, Kozy HM, Mobley WC, Epstein CJ. 2005. Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(1716)65Dn and mouse chromosome 12. Mamm. Genome 16:79-90
95. Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, et al. 2004. Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 480:281-98
96. Zou C, Montagna E, Shi Y, Peters F, Blazquez-Llorca L, et al. 2015. Intraneuronal APP and extracellular Aβindependently cause dendritic spine pathology in transgenic mouse models of Alzheimer's disease. Acta Neuropathol. 129(6):909-20
97. Gouras GK, Willén K, Faideau M. 2014. The inside-out amyloid hypothesis and synapse pathology in Alzheimer's disease. Neurodegener. Dis. 13:142-46
98. Auffret A, Gautheron V, Repici M, Kraftsik R, Mount HT, et al. 2009. Age-dependent impairment of spinemorphology and synaptic plasticity in hippocampalCA1 neurons of a presenilin 1 transgenicmouse model of Alzheimer's disease. J. Neurosci. 29:10144-52
99. Jung CKE, FuhrmannM,Honarnejad K, Van Leuven F, Herms J. 2011. Role of presenilin1 in structural plasticity of cortical dendritic spines in vivo. J. Neurochem. 119:1064-73
100. Sun S, Zhang H, Liu J, Popugaeva E, Xu NJ, et al. 2014. Reduced synaptic STIM2 expression and impaired store-operated calcium entry cause destabilization of mature spines in mutant presenilin mice. Neuron 82:79-93
101. Wang Y, Greig NH, Yu QS,Mattson MP. 2009. Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppressesNMDAcurrents in hippocampus slices. Neurobiol. Aging 30:1061-68
102. Schneider I, Reverse D, Dewachter I, Ris L, Caluwaerts N, et al. 2001. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J. Biol. Chem. 276:11539-44
103. Zaman SH, Parent A, Laskey A, Lee MK, Borchelt DR, et al. 2000. Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial Alzheimer's disease mutation is normalized with a benzodiazepine. Neurobiol. Dis. 7:54-63
104. Barrow PA, Empson RM, Gladwell SJ, Anderson CM, Killick R, et al. 2000. Functional phenotype in transgenic mice expressing mutant human presenilin-1. Neurobiol. Dis. 7:119-26
105. Dewachter I, Ris L, Croes S, Borghgraef P, Devijver H, et al. 2008. Modulation of synaptic plasticity and Tau phosphorylation by wild-type and mutant presenilin1. Neurobiol. Aging 29:639-52
106. Parent A, Linden DJ, Sisodia SS, Borchelt DR. 1999. Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Neurobiol. Dis. 6:56-62
107. Xia D,Watanabe H,Wu B, Lee SH, Li Y, et al. 2015. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease. Neuron 85:967-81
108. Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, et al. 2006. Presenilins form ERCa2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 126:981-93
109. Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I. 2010. Role of presenilins in neuronal calcium homeostasis. J. Neurosci. 30:8566-80
110. Cheung KH, Shineman D, Muller M, Cardenas C, Mei L, et al. 2008. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 58:871-83
111. Cheung KH, Mei L, Mak DO, Hayashi I, Iwatsubo T, et al. 2010. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons. Sci. Signal. 3:ra22
112. Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM. 2005. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J. Neurochem. 94:1711-18
113. Chakroborty S, Goussakov I, Miller MB, Stutzmann GE. 2009. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J. Neurosci. 29:9458-70
114. Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I. 2006. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J. Neurosci. 26:5180-89
115. Honarnejad K, Jung CKE, Lammich S, Arzberger T, Kretzschmar H, Herms J. 2013. Involvement of presenilin holoprotein upregulation in calcium dyshomeostasis of Alzheimer's disease. J. Cell. Mol. Med. 17:293-302
116. Nagaishi M, Arai M, Osawa T, Yokoo H, Hirato J, et al. 2011. An immunohistochemical finding in glioneuronal lesions associated with epilepsy: The appearance of nestin-positive, CD34-positive and tauaccumulating cells. Neuropathology 31:468-75
117. Zheng P, Shultz SR, Hovens CM, Velakoulis D, Jones NC, O'Brien TJ. 2014. Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities. Mol. Neurobiol. 49:1532-39
118. Geddes JF, Vowles GH, Nicoll JA, Revesz T. 1999. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol. 98:171-78
119. Sen A, Thom M, Martinian L, Harding B, Cross JH, et al. 2007. Pathological tau tangles localize to focal cortical dysplasia in older patients. Epilepsia 48:1447-54
120. Suzuki K, Parker CC, Pentchev PG, Katz D, Ghetti B, et al. 1995. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol. 89:227-38
121. Love S, Bridges LR, Case CP. 1995. Neurofibrillary tangles in Niemann-Pick disease type C. Brain 118:119-29
122. Leroy K, Ando K, Laporte V, Dedecker R, Suain V, et al. 2012. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice.Am. J. Pathol. 181:1928-40
123. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, et al. 2011. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31:700-11
124. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. 2007. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316:750-54
125. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG. 2004. Induction of inflammatory mediators and microglial activation inmice transgenic for mutant human P301S tau protein. Am. J. Pathol. 165:1643-52
126. Hoffmann N, Dorostkar M, Blumenstock S, Goedert M, Herms J. 2013. Impaired plasticity of cortical dendritic spines in P301S tau transgenic mice. Acta Neuropathol. Commun. 1:82
127. Nizzari M, Barbieri F, Gentile MT, Passarella D, Caorsi C, et al. 2012. Amyloid-β protein precursor regulates phosphorylation and cellular compartmentalization of microtubule associated protein tau. J. Alzheimer's Dis. 29:211-27
128. Blum D, Herrera F, Francelle L, Mendes T, Basquin M, et al. 2014. Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Hum. Mol. Genet. 24:76-85
129. Zempel H, Luedtke J, Kumar Y, Biernat J, DawsonH, et al. 2013. Amyloid-βoligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J. 32:2920-37
130. Liu C, Gotz J. 2013. Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus. PLOS ONE 8:e84849
131. RosenmannH. 2014. Asparagine endopeptidase cleaves tau and promotes neurodegeneration. Nat.Med. 20:1236-38
132. Zhang Z, Song M, Liu X, Kang SS, Kwon I-S, et al. 2014. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat. Med. 20:1254-62
133. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, et al. 2014. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82:1271-88
134. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, et al. 2013. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. PNAS 110:9535-40
135. de Calignon A, PolydoroM, Suárez-Calvet M, William C, Adamowicz DavidH, et al. 2012. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73:685-97
136. Dujardin S, Lecolle K, Caillierez R, Begard S, ZommerN, et al. 2014. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol. Commun. 2:14
137. Liu L, Drouet V,Wu JW, Witter MP, Small SA, et al. 2012. Trans-synaptic spread of tau pathology in vivo. PLOS ONE 7:e31302
138. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. 2006. Staging of Alzheimer diseaseassociated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112:389-404
139. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, et al. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476-81
140. Kuchibhotla KV, Wegmann S, KopeikinaKJ, Hawkes J, RudinskiyN, et al. 2014. Neurofibrillary tanglebearing neurons are functionally integrated in cortical circuits in vivo. PNAS 111:510-14
141. PolydoroM, Dzhala VI, Pooler AM,Nicholls SB,McKinney AP, et al. 2014. Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. Acta Neuropathol. 127:257-70
142. Yoshiyama Y, Higuchi M, Zhang B, Huang S-M, Iwata N, et al. 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337-51
143. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, et al. 2010. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68:1067-81
144. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. 2010. Co-occurrence of Alzheimer's disease β-amyloid and tau pathologies at synapses. Neurobiol. Aging 31:1145-52
145. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, et al. 2010. Dendritic function of tau mediates amyloid-βtoxicity in Alzheimer's disease mouse models. Cell 142:387-97
146. Harris JA, Koyama A, Maeda S, Ho K, Devidze N, et al. 2012. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLOS ONE 7:e45881
147. TaiH-C, Serrano-Pozo A,Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. 2012. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am. J. Pathol. 181:1426-35
148. TaiH-C,Wang B, Serrano-Pozo A, FroschM, Spires-JonesT,Hyman B. 2014. Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer's disease. Acta Neuropathol. Commun. 2:146
149. Mondragón-Rodríguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, et al. 2012. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptordependent tau phosphorylation. J. Biol. Chem. 287:32040-53
150. Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-Brown MA, et al. 2010. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp. Neurol. 223:385-93
151. Liu X, Erikson C, Brun A. 1996. Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. Dementia 7:128-34
152. Mocanu M-M, Nissen A, Eckermann K, Khlistunova I, Biernat J, et al. 2008. The potential for β-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous tau in inducible mouse models of tauopathy. J. Neurosci. 28:737-48
153. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, et al. 2006. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 169:599-616
154. Aguzzi A, Heikenwalder M, Polymenidou M. 2007. Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell Biol. 8:552-61
155. Jeffrey M, McGovern G, Siso S, Gonzalez L. 2011. Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical disease. Acta Neuropathol. 121:113-34
156. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, et al. 2000. Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infectedmurine hippocampus. Neuropathol. Appl. Neurobiol. 26:41-54
157. Fuhrmann M, Mitteregger G, Kretzschmar H, Herms J. 2007. Dendritic pathology in prion disease starts at the synaptic spine. J. Neurosci. 27:6224-33
158. Siskova Z, Reynolds RA, O'Connor V, Perry VH. 2013. Brain region specific pre-synaptic and postsynaptic degeneration are early components of neuropathology in prion disease. PLOS ONE 8:e55004
159. Gray BC, Siskova Z, Perry VH, O'Connor V. 2009. Selective presynaptic degeneration in the synaptopathy associated with ME7-induced hippocampal pathology. Neurobiol. Dis. 35:63-74
160. Jamieson E, JeffreyM, Ironside JW, Fraser JR. 2001. Apoptosis and dendritic dysfunction precede prion protein accumulation in 87V scrapie. NeuroReport 12:2147-53
161. Chiesa R, Drisaldi B, Quaglio E, Migheli A, Piccardo P, et al. 2000. Accumulation of protease-resistant prion protein (PrP) and apoptosis of cerebellar granule cells in transgenic mice expressing a PrP insertional mutation. PNAS 97:5574-79
162. JeffreyM, Goodsir C, McGovern G, Barmada SJ,Medrano AZ, Harris DA. 2009. Prion protein with an insertionalmutation accumulates on axonal and dendritic plasmalemma and is associated with distinctive ultrastructural changes. Am. J. Pathol. 175:1208-17
163. Zhou M, OttenbergG, Sferrazza GF, Lasmezas CI. 2012. Highly neurotoxic monomericα-helical prion protein. PNAS 109:3113-18
164. Simoneau S, Rezaei H, Sales N, Kaiser-Schulz G, Lefebvre-Roque M, et al. 2007. In vitro and in vivo neurotoxicity of prion protein oligomers. PLOS Pathog. 3:e125
165. Novitskaya V, Bocharova OV, Bronstein I, Baskakov IV. 2006. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 281:13828-36
166. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, et al. 2012. Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature 485:507-11
167. Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, et al. 2005. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64:545-47
168. McNeill TH, Brown SA, Rafols JA, Shoulson I. 1988. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res. 455:148-52
169. Neuner J, Ovsepian SV, Dorostkar M, Filser S, Gupta A, et al. 2014. Pathological α-synuclein impairs adult-born granule cell development and functional integration in the olfactory bulb. Nat. Commun. 5:3915
170. Diogenes MJ, Dias RB, Rombo DM, Vicente Miranda H, Maiolino F, et al. 2012. Extracellular alphasynuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J. Neurosci. 32:11750-62
171. Hüls S,Hogen T, Vassallo N, Danzer KM,Hengerer B, et al. 2011. AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α-synuclein oligomers. J. Neurochem. 117:868-78
172. Collingridge GL, Isaac JT, Wang YT. 2004. Receptor trafficking and synaptic plasticity. Nat. Rev. Neurosci. 5:952-62
173. Bliss TV, Collingridge GL. 1993. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-39
174. Pozo K, Goda Y. 2010. Unraveling mechanisms of homeostatic synaptic plasticity. Neuron 66:337-51
175. Kramer ML, Schulz-Schaeffer WJ. 2007. Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27:1405-10
176. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. 2010. A pathologic cascade leading to synaptic dysfunction in α-synuclein-induced neurodegeneration. J. Neurosci. 30:8083-95
177. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, et al. 2010. Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65:66-79
178. Soper JH, Roy S, Stieber A, Lee E, Wilson RB, et al. 2008. α-Synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol. Biol. Cell 19:1093-103
179. Gitler D, Cheng Q, Greengard P, Augustine GJ. 2008. Synapsin IIa controls the reserve pool of glutamatergic synaptic vesicles. J. Neurosci. 28:10835-43
180. Chandra S,Gallardo G, Fernandez-Chacon R, SchluterOM, Sudhof TC. 2005.α-Synuclein cooperates with CSPαin preventing neurodegeneration. Cell 123:383-96
181. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, et al. 2006. α-Synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 26:11915-22
182. Ferrante RJ, Kowall NW, Richardson EP Jr. 1991. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: A combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 11:3877-87
183. Graveland GA, Williams RS, DiFiglia M. 1985. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227:770-73
184. Sotrel A, Williams RS, Kaufmann WE, Myers RH. 1993. Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: A quantitative Golgi study. Neurology 43:2088-96
185. Spires TL, Grote HE, Garry S, Cordery PM, Van Dellen A, et al. 2004. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur. J. Neurosci. 19:2799-807
186. Nithianantharajah J, Barkus C, Vijiaratnam N, Clement O, Hannan AJ. 2009. Modeling brain reserve: experience-dependent neuronal plasticity in healthy and Huntington's disease transgenic mice. Am. J. Geriatr. Psychiatry 17:196-209
187. Heck N, Betuing S, Vanhoutte P, Caboche J. 2012. A deconvolution method to improve automated 3D-analysis of dendritic spines: application to a mouse model of Huntington's disease. Brain Struct. Funct. 217:421-34
188. Murmu RP, Li W, Holtmaat A, Li JY. 2013. Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's disease. J. Neurosci. 33:12997-3009
189. Li JY, Conforti L. 2013. Axonopathy in Huntington's disease. Exp. Neurol. 246:62-71
190. Ratnavalli E, Brayne C, Dawson K, Hodges JR. 2002. The prevalence of frontotemporal dementia. Neurology 58:1615-21
191. Rohrer JD, Isaacs AM,Mizielinska S,Mead S, Lashley T, et al. 2015. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol. 14:291-301
192. Gorrie GH, Fecto F, Radzicki D,Weiss C, Shi Y, et al. 2014. Dendritic spinopathy in transgenic mice expressing ALS/dementia-linked mutant UBQLN2. PNAS 111:14524-29
193. Thal DR, Rub U, Orantes M, Braak H. 2002. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791-800
194. Braak H, Thal DR,Ghebremedhin E,Del Tredici K. 2011. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70:960-69
195. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, et al. 2011. Human apoE isoforms differentially regulate brain amyloid-βpeptide clearance. Sci. Transl. Med. 3:89ra57
196. Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, et al. 1998. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 55:326-35
197. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, et al. 2003. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60:1495-500
198. NearyD, Snowden JS,Gustafson L, Passant U, StussD, et al. 1998. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51:1546-54
199. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, et al. 2011. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122:111-13
200. NeumannM, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. 2006. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130-33
201. NeumannM,RademakersR,Roeber S, Baker M, KretzschmarHA, Mackenzie IRA. 2009.A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:2922-31
202. Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, et al. 2008. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum. Mol. Genet. 17:3631-42
203. PrinzM, Heikenwalder M, Junt T, Schwarz P, GlatzelM, et al. 2003. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature 425:957-62
204. HeadMW,Ironside JW. 2012. Review:Creutzfeldt-Jakob disease: prion protein type, disease phenotype and agent strain. Neuropathol. Appl. Neurobiol. 38:296-310
205. Parchi P, Strammiello R, Giese A, Kretzschmar H. 2011. Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol. 121:91-112
206. De Rosa P, Marini ES, Gelmetti V, Valente EM. 2015. Candidate genes for Parkinson disease: lessons from pathogenesis. Clin. Chim. Acta 449:68-76
207. Reiner A, Dragatsis I, Dietrich P. 2011. Genetics and neuropathology of Huntington's disease. Int. Rev. Neurobiol. 98:325-72
208. Ingre C, Roos PM, Piehl F, Kamel F, Fang F. 2015. Risk factors for amyotrophic lateral sclerosis. Clin. Epidemiol. 7:181-93
209. Lattante S, Ciura S, Rouleau GA, Kabashi E. 2015. Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). Trends Genet. 31:263-73
210. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, et al. 2013. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339:1335-38